Jacqueline B. Stone
Memorial Sloan Kettering Cancer Center
20 Papers
24 Citations
Jacqueline B. Stone is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Medicine & Ibrutinib. The author has an hindex of 9, co-authored 16 publications. Previous affiliations of Jacqueline B. Stone include Cornell University.
Chat about Author
Papers
Cancer-treatment-induced neurotoxicity—focus on newer treatments
TL;DR: Familiarity with the neurological syndromes associated with cancer treatments enables clinicians to use the appropriate treatment for the underlying malignancy while minimizing the risk of neurological damage, which might preserve patients' quality of life.
Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma.
Christian Grommes,Christian Grommes,Sarah S. Tang,Julia Wolfe,Thomas Kaley,Mariza Daras,Elena Pentsova,Anna F. Piotrowski,Jacqueline B. Stone,Andrew L. Lin,Craig Nolan,Malbora Manne,Paolo Codega,Carl Campos,Agnes Viale,Alissa A. Thomas,Michael F. Berger,Michael F. Berger,Vaios Hatzoglou,Anne S. Reiner,Katherine S. Panageas,Lisa M. DeAngelis,Ingo K. Mellinghoff +22 more
TL;DR: The combination of ibrutinib, HD-MTX, and rituximab was tolerated with an acceptable safety profile and sustained tumor responses were associated with clearance of ctDNA from the CSF.
212
Recurrent thromboembolic events after ischemic stroke in patients with cancer
Babak B. Navi,Samuel Singer,Alexander E Merkler,Natalie T. Cheng,Jacqueline B. Stone,Hooman Kamel,Costantino Iadecola,Mitchell S.V. Elkind,Lisa M. DeAngelis +8 more
TL;DR: Patients with acute ischemic stroke in the setting of active cancer (especially adenocarcinoma) face a substantial short-term risk of recurrent isChemic stroke and other types of thromboembolism.
158
Genomic correlates of disease progression and treatment response in prospectively characterized gliomas
Philip Jonsson,Andrew L. Lin,Robert J. Young,Natalie DiStefano,David M. Hyman,Bob T. Li,Michael F. Berger,Ahmet Zehir,Marc Ladanyi,David B. Solit,Angela G. Arnold,Zsofia K. Stadler,Diana Mandelker,Michael E. Goldberg,Juliann Chmielecki,Maryam Pourmaleki,Shahiba Ogilvie,Shweta S. Chavan,Andrew T. McKeown,Malbora Manne,Allison Hyde,Kathryn Beal,T. Jonathan Yang,Craig Nolan,Elena Pentsova,Antonio Omuro,Igor T. Gavrilovic,Thomas Kaley,Eli L. Diamond,Jacqueline B. Stone,Christian Grommes,Adrienne Boire,Mariza Daras,Anna F. Piotrowski,Alexandra Miller,Philip H. Gutin,Timothy A. Chan,Viviane Tabar,Cameron Brennan,Marc K. Rosenblum,Lisa M. DeAngelis,Ingo K. Mellinghoff,Barry S. Taylor +42 more
TL;DR: These data reveal genomic correlates of disease progression and treatment response in diverse types of glioma and highlight the potential utility of incorporating genomic information into the clinical decision-making for patients with gliomas.
Cryptogenic Subtype Predicts Reduced Survival Among Cancer Patients With Ischemic Stroke
Babak B. Navi,Samuel Singer,Alexander E Merkler,Natalie T. Cheng,Jacqueline B. Stone,Hooman Kamel,Costantino Iadecola,Mitchell S.V. Elkind,Lisa M. DeAngelis +8 more
TL;DR: A retrospectively analyzed all adult patients with active systemic cancer diagnosed with acute ischemic stroke at a tertiary care cancer center from 2005 through 2009 to find out whether cryptogenic stroke is independently associated with reduced survival in patients withactive cancer and isChemic stroke.
88